CEO Hiroshi Miyake


Hiroshi Miyake, Ph.D., is a co-founder of Chordia Therapeutics and he has served as President and CEO and acted as a member of the board of directors since Chordia’s incorporation in November 2017. He has over 20 years of experience in drug discovery and his team has delivered programs to the clinical stage six times. Before the foundation of Chordia, he served as the site head of the oncology drug discovery unit at Takeda Pharmaceuticals. He earned his B.S. from Osaka University and his Ph.D. in Pharmacology from the University of Tokyo.